Cardiovascular Systems, Inc. (CSI), now a part of Abbott, specialized in innovative solutions for the treatment of peripheral and coronary artery disease through its proprietary orbital atherectomy systems. CSI’s flagship technologies include the Diamondback 360® Peripheral Orbital Atherectomy System and the Diamondback 360® Coronary Orbital Atherectomy System, both designed to modify calcified plaque and improve vessel compliance prior to stent placement or balloon angioplasty.
These systems use a diamond-coated crown that orbits within the vessel, sanding away plaque while preserving healthy tissue and facilitating better device delivery. CSI’s focus on challenging arterial disease—particularly in heavily calcified lesions—made it a valuable addition to Abbott’s vascular portfolio following its acquisition in 2023, further expanding minimally invasive treatment options for complex cardiovascular cases.